Compound Sophorae Decoction: treating ulcerative colitis by affecting multiple metabolic pathways

Zong-Chao Hong,Quan Cai,He-Zhen Wu,Yan-Fang Yang,Heng Fan,Xue-Yun Duan,Zong-Chao HONG,Quan CAI,He-Zhen WU,Yan-Fang YANG,Heng FAN,Xue-Yun DUAN
DOI: https://doi.org/10.1016/s1875-5364(21)60029-8
IF: 3.887
2021-04-01
Chinese Journal of Natural Medicines
Abstract:Ulcerative colitis (UC) is a chronic refractory non-specific intestinal inflammatory disease that is difficult to be cured. The discovery of new ulcerative colitis-related metabolite biomarkers may help further understand UC and facilitate early diagnosis. It may also provide a basis for explaining the mechanism of drug action in the treatment of UC. Compound Sophorae Decoction (CSD) is an empirical formula used in the clinical treatment of UC. Although it is known to be efficacious, its mechanism of action in the treatment of UC is unclear. The purpose of this study was to investigate the changes in endogenous substances in UC rats and the effects of CSD on metabolic pathways using the metabonomics approach. Metabolomics studies in rats with UC and normal rats were performed using LC-MS/MS. Rats with UC induced using TNBS enema were used as the study models. Metabolic profiling and pathway analysis of biomarkers was performed using statistical and pathway enrichment analyses. 36 screened potential biomarkers were found to be significantly different between the UC and the normal groups; it was also found that CSD could modulate the levels of these potential biomarkers. CSD was found to be efficacious in UC by regulating multiple metabolic pathways.
pharmacology & pharmacy,integrative & complementary medicine
What problem does this paper attempt to address?
The paper aims to explore the mechanism of Compound Sophorae Decoction (CSD) in treating Ulcerative Colitis (UC) by affecting metabolic pathways. Specifically, the study utilized metabolomics methods and analyzed the changes in endogenous substances in UC rat models and normal rats through LC-MS/MS technology. The research found that there are 36 potential biomarkers with significant differences between the UC group and the normal group, and CSD can regulate the levels of these potential biomarkers, thereby confirming the effectiveness and mechanism of CSD in treating UC.